Infectious Disease Molecular Target Discovery
Molecular diagnostics, employing a target‐specific nucleic acid probe and, usually, an in vitro
amplification step to detect and analyse DNA and/or RNA in a biological sample, has now entered the mainstream infectious disease diagnostics testing sector in areas such as clinical, veterinary, food, environmental and industrial. A key component in these Nucleic Acid‐based diagnostic tests (NAT) is the choice of the nucleic acid target chosen to detect and identify the microorganism of interest. The MDRG has identified and evaluated a range of platform nucleic acid targets to identify and distinguish across all bacterial, fungal or yeast species, along with nucleic acid targets for the use of specific individual microorganisms. These proprietary nucleic acid targets are all patent protected by NUI Galway.